An Inactivated Antibiotic-Exposed Whole-Cell Vaccine Enhances Bactericidal Activities Against Multidrug-Resistant Acinetobacter Baumannii

Overview

Journal Sci Rep

Specialty Science

Date 2016 Mar 1

PMID 26923424

Citations 14

Authors

Meng-Hooi Shu

NorAziyah MatRahim

NurAsyura NorAmdan

Sui-Ping Pang

Sharina H Hashim

Wai-Hong Phoon

Sazaly AbuBakar

Affiliations

Soon will be listed here.

Abstract

Vaccination may be an alternative treatment for infection with multidrug-resistance (MDR) Acinetobacter baumannii. The study reported here evaluated the bactericidal antibody responses following immunization of mice using an inactivated whole-cell vaccine derived from antibiotic-exposed MDR A. baumannii (I-M28-47-114). Mice inoculated with I-M28-47 (non-antibiotic-exposed control) and I-M28-47-114 showed a high IgG antibody response by day 5 post-inoculation. Sera from mice inoculated with I-M28-47-114 collected on day 30 resulted in 80.7 ± 12.0% complement-mediated bacteriolysis in vitro of the test MDR A. baumannii treated with imipenem, which was a higher level of bacteriolysis over sera from mice inoculated with I-M28-47. Macrophage-like U937 cells eliminated 49.3 ± 11.6% of the test MDR A. baumannii treated with imipenem when opsonized with sera from mice inoculated with I-M28-47-114, which was a higher level of elimination than observed for test MDR A. baumannii opsonized with sera from mice inoculated with I-M28-47. These results suggest that vaccination with I-M28-47-114 stimulated antibody responses capable of mounting high bactericidal killing of MDR A. baumannii. Therefore, the inactivated antibiotic-exposed whole-cell vaccine (I-M28-47-114) has potential for development as a candidate vaccine for broad clearance and protection against MDR A. baumannii infections.

Citing Articles

Multidrug resistant : A study on its pathogenesis and therapeutics.

Mukhopadhyay H, Bairagi A, Mukherjee A, Prasad A, Roy A, Nayak A Curr Res Microb Sci. 2025; 8():100331.

PMID: 39802320 PMC: 11718326. DOI: 10.1016/j.crmicr.2024.100331.

The Promising Potential of Reverse Vaccinology-Based Next-Generation Vaccine Development over Conventional Vaccines against Antibiotic-Resistant Bacteria.

Khalid K, Poh C Vaccines (Basel). 2023; 11(7).

PMID: 37515079 PMC: 10385262. DOI: 10.3390/vaccines11071264.

TonB-Dependent Receptor Protein Displayed on Spores of Stimulates Protective Immune Responses against .

MatRahim N, Jones K, Keegan B, Strych U, Zhan B, Lee H Vaccines (Basel). 2023; 11(6).

PMID: 37376495 PMC: 10302887. DOI: 10.3390/vaccines11061106.

Using an Aluminum Hydroxide-Chitosan Matrix Increased the Vaccine Potential and Immune Response of Mice against Multi-Drug-Resistant .

Deusdara T, Felix M, de S Brito H, Cangussu E, de S Moura W, Albuquerque B Vaccines (Basel). 2023; 11(3).

PMID: 36992253 PMC: 10058140. DOI: 10.3390/vaccines11030669.

Non-antibiotic prevention and treatment against infection: Are vaccines and adjuvants effective strategies?.

Hu Y, Zhang X, Deng S, Yue C, Jia X, Lyu Y Front Microbiol. 2023; 14:1049917.

PMID: 36760499 PMC: 9905804. DOI: 10.3389/fmicb.2023.1049917.

References

Oncul O, Keskin O, Acar H, Kucukardali Y, Evrenkaya R, Atasoyu E . Hospital-acquired infections following the 1999 Marmara earthquake. J Hosp Infect. 2002; 51(1):47-51. DOI: 10.1053/jhin.2002.1205. View

Shu M, Appleton D, Zandi K, AbuBakar S . Anti-inflammatory, gastroprotective and anti-ulcerogenic effects of red algae Gracilaria changii (Gracilariales, Rhodophyta) extract. BMC Complement Altern Med. 2013; 13:61. PMC: 3606449. DOI: 10.1186/1472-6882-13-61. View

Estein S, Cheves P, Fiorentino M, Cassataro J, Paolicchi F, Bowden R . Immunogenicity of recombinant Omp31 from Brucella melitensis in rams and serum bactericidal activity against B. ovis. Vet Microbiol. 2004; 102(3-4):203-13. DOI: 10.1016/j.vetmic.2004.05.004. View

Pier G, Thomas D, Small G, Siadak A, Zweerink H . In vitro and in vivo activity of polyclonal and monoclonal human immunoglobulins G, M, and A against Pseudomonas aeruginosa lipopolysaccharide. Infect Immun. 1989; 57(1):174-9. PMC: 313063. DOI: 10.1128/iai.57.1.174-179.1989. View

Cripps A, Dunkley M, Clancy R . Mucosal and systemic immunizations with killed Pseudomonas aeruginosa protect against acute respiratory infection in rats. Infect Immun. 1994; 62(4):1427-36. PMC: 186298. DOI: 10.1128/iai.62.4.1427-1436.1994. View

Misbah S, AbuBakar S, Hassan H, Hanifah Y, Yusof M . Antibiotic susceptibility and REP-PCR fingerprints of Acinetobacter spp. isolated from a hospital ten years apart. J Hosp Infect. 2004; 58(4):254-61. DOI: 10.1016/j.jhin.2004.07.007. View

Cripps A, Peek K, Dunkley M, Vento K, Marjason J, McIntyre M . Safety and immunogenicity of an oral inactivated whole-cell pseudomonas aeruginosa vaccine administered to healthy human subjects. Infect Immun. 2006; 74(2):968-74. PMC: 1360303. DOI: 10.1128/IAI.74.2.968-974.2006. View

Zaidi T, Priebe G, Pier G . A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection. Infect Immun. 2006; 74(2):975-83. PMC: 1360306. DOI: 10.1128/IAI.74.2.975-983.2006. View

Scott P, Deye G, Srinivasan A, Murray C, Moran K, Hulten E . An outbreak of multidrug-resistant Acinetobacter baumannii-calcoaceticus complex infection in the US military health care system associated with military operations in Iraq. Clin Infect Dis. 2007; 44(12):1577-84. DOI: 10.1086/518170. View

10.

Peleg A, Seifert H, Paterson D . Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev. 2008; 21(3):538-82. PMC: 2493088. DOI: 10.1128/CMR.00058-07. View

11.

Billips B, Yaggie R, Cashy J, Schaeffer A, Klumpp D . A live-attenuated vaccine for the treatment of urinary tract infection by uropathogenic Escherichia coli. J Infect Dis. 2009; 200(2):263-72. DOI: 10.1086/599839. View

12.

Zavascki A, Carvalhaes C, Picao R, Gales A . Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy. Expert Rev Anti Infect Ther. 2009; 8(1):71-93. DOI: 10.1586/eri.09.108. View

13.

McConnell M, Pachon J . Active and passive immunization against Acinetobacter baumannii using an inactivated whole cell vaccine. Vaccine. 2010; 29(1):1-5. DOI: 10.1016/j.vaccine.2010.10.052. View

14.

McConnell M, Dominguez-Herrera J, Smani Y, Lopez-Rojas R, Docobo-Perez F, Pachon J . Vaccination with outer membrane complexes elicits rapid protective immunity to multidrug-resistant Acinetobacter baumannii. Infect Immun. 2010; 79(1):518-26. PMC: 3019872. DOI: 10.1128/IAI.00741-10. View

15.

Lindow J, Fimlaid K, Bunn J, Kirkpatrick B . Antibodies in action: role of human opsonins in killing Salmonella enterica serovar Typhi. Infect Immun. 2011; 79(8):3188-94. PMC: 3147595. DOI: 10.1128/IAI.05081-11. View

16.

McConnell M, Rumbo C, Bou G, Pachon J . Outer membrane vesicles as an acellular vaccine against Acinetobacter baumannii. Vaccine. 2011; 29(34):5705-10. DOI: 10.1016/j.vaccine.2011.06.001. View

17.

Kempf M, Rolain J . Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options. Int J Antimicrob Agents. 2011; 39(2):105-14. DOI: 10.1016/j.ijantimicag.2011.10.004. View

18.

Barnes M, Weiss A . Activation of the complement cascade by Bordetella pertussis. FEMS Microbiol Lett. 2003; 220(2):271-5. DOI: 10.1016/S0378-1097(03)00132-0. View